Skip to content
Screener

Nuvation Bio NUVB Other Income (Expense)

Other Income (Expense) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$61M+112%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$2.51M-513%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$5M-37.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$563M-760%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$5.79M+47.0%
Eli Lilly logo
Eli LillyLLY
$269M+399%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Realized gain (loss) on marketable securities9(1)172
Net gain (loss) on disposal of fixed assets1(34)1(34)
Other income (expense)5(14)4431,438
Total other (expense) income, net(11,804)4,582(10,288)10,350
Loss before income taxes(62,840)(59,007)(57,443)(112,243)
Provision for income taxes
Net loss$(62,840)$(59,007)$(57,443)$(112,243)
Net loss per share attributable to common stockholders, basic and diluted$(0.18)$(0.17)$(0.17)$(0.33)

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's other income (expense)?
Nuvation Bio (NUVB) reported other income (expense) of -$11.8M in Q2 2026.
How has Nuvation Bio's other income (expense) changed year-over-year?
Nuvation Bio's other income (expense) decreased by 357.6% year-over-year, from $4.58M to -$11.8M.
What is the long-term trend for Nuvation Bio's other income (expense)?
Over 3 years (2021 to 2024), Nuvation Bio's other income (expense) has grown at a 56.3% compound annual growth rate (CAGR), from $6.47M to $24.69M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Nuvation Bio's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude